Jennifer Arnold, MD

Jennifer Arnold, MD

Assistant Professor, Neurology
Neurology

    About me

    Gender

    Female

    Education & training

    Positions
    Neurologist
    Medical School
    MD, University of Illinois
    Doctorate Degree
    Ph.D. Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
    Undergraduate Degree
    BS Biology, Southeast Missouri State University
    Residency
    Neurology, University of Michigan
    Fellowship
    Neurodegenerative Diseases, University of Michigan

    Clinical trials

    Trial
    Neuroscience Institute

    GN40040: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients with Moderate Alzheimer's Disease

    Active not recruiting

    GN40040:  The purpose of this study is to assess the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with moderate Alzheimer's disease.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    Annovis - A Randomized, Double-Blind, Placebo-Controlled, Dose-ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer's Disease

    Active recruiting

    The purpose of this study is to assess the efficacy and safety of Buntanetap in participants with mild to moderate Alzheimer's Disease participants.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Annovis - A Randomized, Double-Blind, Placebo-Controlled, Dose-ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer's Disease

    Active recruiting

    The purpose of this study is to assess the efficacy and safety of Buntanetap in participants with mild to moderate Alzheimer's Disease participants.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects with Mild to Moderate Alzheimer's Disease

    Active not recruiting

    ATH-1017-AD-203: The purpose of this study is to determine the safety and tolerability of ATH-1017 in patients with mild to moderate Alzheimer's disease.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Roche: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of MTAU9937A in Patients with Moderate Alzheimer's Disease

    Active not recruiting

    The purpose of this study is to assess the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with moderate Alzheimer's disease.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    Roche: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of MTAU9937A in Patients with Moderate Alzheimer's Disease

    Active not recruiting

    The purpose of this study is to assess the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with moderate Alzheimer's disease.

    Contact: Stephanie Kohlrus 217-545-3013

    Related articles

    Arnold

    Meet Jennifer Arnold, MD

    What brought you to SIU Medicine? I was born in Springfield and spent all of my childhood here, leaving only to go to college, then medical and graduate school. I always knew I wanted to return home